Conavi Medical Closes $20M Public Offering

Conavi Medical, a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, recently announced that it has closed its previously announced, upsized equity offering for aggregate gross proceeds of $20 million (the "Offering"). The net proceeds from the Offering will be used to advance and complete the development and pre-clinical testing of its Novasight 3.0 technology, with the goal of submitting a 510(k) clearance application to the U.S. Food and Drug Administration in Q3 of 2025.

Conavi Medical is an OBIO® member, alumnus of our BDSP™, CAAP® and WiHI programs, and presented at the OBIO® Investment Summit.